Discover how next-generation kinase inhibitors are transforming clinical therapy byovercoming resistance and enhancing ...

Dublin, Feb. 24, 2025 (GLOBE NEWSWIRE) -- The "Thymidine Kinase 2 Deficiency - Market Insight, Epidemiology, and Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. The ...

The following is a summary of “Pyruvate Kinase Function Correlates With Red Blood Cell Properties and Clinical Manifestations ...

Janus kinase (JAK) inhibitors look to be a good treatment option for the newly recognized, rare autoimmune disease known as ...

Tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) were recognized to cause endocrine adverse reactions (EARs). However, combination therapy-associated EARs are still ...

A new review published in Genes & Diseases explores the multifaceted role of FAM20C, a Golgi protein kinase, in disease ...

Eisai will maintain the rights to tasurgratinib worldwide outside of the licensed regions.

Hematopoietic and lymphocytic neoplasms (HLNs) are a diverse group of malignancies affecting blood and lymphatic systems, with outcomes varying from manageable conditions to fatal diseases.

The results showed statistically significant and clinically meaningful improvement in progression-free survival compared with ...

Laboratory of Molecular Nutrition and Immunity, College of Animal Science and Technology, Northeast Agricultural University, Harbin 150030, People’s Republic of China ...

Panelists discuss how Bruton tyrosine kinase (BTK) inhibitors have transformed the treatment paradigm for patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), especially in ...

Scientists at VCU Massey Comprehensive Cancer Center have identified an innovative combination of treatment strategies that ...